Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors

To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.

1. Percutaneous microwave ablation or intratumor injection of drug-eluting beads to destroy cancer cells to release tumor-specific antigens
2. Intratumor injection of type A/C CpG-ODN with or without infusion of CAR-T cells secreting scFv against OX40
3. Assessing side effects and therapeutic efficacy after the combined treatments

Inclusion Criteria:

• Solid advanced malignant tumors
• Age between18 and 80 years
• Life expectancy is greater than three months

Exclusion Criteria:

• Benign tumor
• Life expectancy is less than three months
• Serious medical comorbidity
• Others